ABMD - DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue

SDI Productions/E+ via Getty Images A Data Safety Monitoring Board ("DSMB") has recommended that Abiomed's (ABMD) DanGer Shock trial of its Impella CP heart pump in patients with cardiogenic shock should continue, according to Piper Sandler.Citing a tweet from one of the lead investigators of that trial, Piper said that the DSMB told the company it can continue following a pre-specified interim analysis of 180 patients over 180 days."In our view, this suggests that the results are trending in the right direction (they would have halted it for futility if negative)," according to Piper.Abiomed shares are down 1.6% to $286.54 in afternoon trading.

For further details see:

DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue